Muborakkhon Zokirova

6 ta ish

Tashkent Medical Academy, Internal Disease №1, Tashkent, Uzbekistan

1. Level of thrombin activated fibrinolysis inhibitor in patients with ischemic stroke

   N. M. Nurillaeva, Muborakkhon Zokirova

   MaqolaNeurological Disorders and TreatmentsAtherosclerosis20210 iqtibos

   ABIABI:AkademIndex/openalex/2021.article.008318

2. Mobilization of healthcare systems of different countries during the pandemic coronavirus

   S. G. Nazarova, Shakhnoza Iskandarova, Muborakkhon Zokirova +2

   MaqolaHermeneutics and Narrative IdentityZenodo (CERN European Organization for Nuclear Research)20210 iqtibos

   ABIABI:AkademIndex/openalex/2021.article.012043

3. Assessment of atherosclerotic lesions of the carotid arteries depending on the smoking index in patients with coronary artery disease

   Muborakkhon Zokirova, S. Shukurdjanova, M. Zubaydullaeva +1

   MaqolaCardiovascular Disease and AdiposityAtherosclerosis20220 iqtibos

   ABIABI:AkademIndex/openalex/2022.article.007499

4. Clinical and diagnostic significance of plasminogen activator inhibitor type 1 in the early development of coronary heart disease

   Н Нуриллаева, Н А Хасанова, Muborakkhon Zokirova

   MaqolaApelin-related biomedical researchScience and Innovations in Medicine20230 iqtibos

   ABIABI:AkademIndex/openalex/2023.article.004836

5. STUDIES OF THE CORRELATION OF THE TAFI GENE WITH ARTERIAL HYPERTENSION IN PATIENTS WITH CORONARY HEART DISEASE

   Muborakkhon Zokirova

   MaqolaHealthcare Systems and Public HealthJournal of Hypertension20230 iqtibos

   ABIABI:AkademIndex/openalex/2023.article.008061

6. Assessment of cardiovascular complications during chemotherapy in patients with acute lymphoblastic leukemia

   Muborakkhon Zokirova, Abdurakhman Kayumov, Н Нуриллаева

   MaqolaChemotherapy-induced cardiotoxicity and mitigationAtherosclerosis20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.007915